Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

Haddad, Rudy M.; Kennedy, Cassie C.; Caples, Sean M.; Tracz, Michal J.; Boloña, Enrique R.; Sideras, Kostandinos; Uraga, Maria V.; Erwin, Patricia J.; Montori, Victor M.
January 2007
Mayo Clinic Proceedings;Jan2007, Vol. 82 Issue 1, p29
Academic Journal
OBJECTIVE: To conduct a systematic review and meta-analysis of randomized trials that assessed the effect of testosterone use on cardiovascular events and risk factors in men with different degrees of androgen deficiency. METHODS: Librarian-designed search strategies were used to search the MEDLINE (1966 to October 2004), EMBASE (1988 to October 2004), and Cochrane CENTRAL (inception to October 2004) databases. The database search was performed again in March 2005. We also reviewed reference lists from included studies and content expert files. Eligible studies were randomized trials that compared any formulation of commercially available testosterone with placebo and that assessed cardiovascular risk factors (lipid fractions, blood pressure, blood glucose), cardiovascular events (cardiovascular death, nonfatal myocardial infarction, angina or claudication, revascularization, stroke), and cardiovascular surrogate end points (ie, laboratory tests indicative of cardiac or vascular disease). Using a standardized data extraction form, we collected data on participants, testosterone administration, and outcome measures. We assessed study quality with attention to allocation concealment, blinding, and loss to follow-up. RESULTS: The 30 trials included 1642 men, 808 of whom were treated with testosterone. Overall, the trials had limited reporting of methodological features that prevent biased results (only 6 trials reported allocation concealment), enrolled few patients, and were of brief duration (only 4 trials followed up patients for >1 year). The median loss to follow-up across all 30 trials was 9%. Testosterone use in men with low testosterone levels led to inconsequential changes in blood pressure and glycemia and in all lipid fractions (total cholesterol: odds ratio [OR], -0.22; 95% confidence interval [Cl], -0.71 to 0.27; high-density lipoprotein cholesterol: OR, -0.04; 95% Cl, -039 to 0.30; low-density Iipoprotein cholesterol: OR, 0.06; 95% Cl, -0.30 to 0.42; and triglycerides: OR, -0.27; 95% Cl, -0.61 to 0.08); results were similar in patients with low-normal to normal testosterone levels. The OR between testosterone use and any cardiovascular event pooled across trials that reported these events (n=6) was 1.82 (95% Cl, 0.78 to 4.23). Several trials failed to report data on measured outcomes. For reasons we could not explain statistically, the results were inconsistent across trials. CONCLUSION: Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects. Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.


Related Articles

  • Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. Lin Xu; Freeman, Guy; Cowling, Benjamin J.; Schooling, C. Mary // BMC Medicine;2013, Vol. 11 Issue 1, p1 

    Background: Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of androgens are thought to promote cardiovascular disease. Methods: A...

  • Longitudinal Relation between Endogenous Testosterone and Cardiovascular Disease Risk Factors in Middle-aged Men. Zmuda, Joseph M.; Cauley, Jane A.; Kriska, Andrea; Glynn, Nancy W.; Gutai, James P.; Kuller, Lewis H. // American Journal of Epidemiology;1997, Vol. 146 Issue 8, p609 

    The present study examined lifestyle and behavioral correlates of the change in total testosterone over 13 years in 66 men aged 41–61 years who were former participants of the Multiple Risk Factor Intervention Trial (MRFIT) at the Pittsburgh, Pennsylvania, center. The authors also...

  • Effects of Testosterone on the Number of Circulating Endothelial Progenitor Cells in Wistar Rats. Bahrani, Saeide; Haghjooy Javanmard, Shaghayegh; Sadat Mortazavi, Zahra; Motamer, Maryam; Nasr Esfahani, Farid // Journal of Isfahan Medical School;11/5/2012, Vol. 30 Issue 203, p1 

    Background: Cardiovascular diseases (CVDs) are the main cause of mortality worldwide. The fact that men are more affected than women supports the hypothesis that testosterone is a risk factor of CVD. Endothelial progenitor cells (EPC) have an important role in vascular repair and angiogenesis....

  • Testosterone deficiency and replacement: Myths and realities. Grober, Ethan D. // Canadian Urological Association Journal;jui/aou2014 supplement 5, Vol. 8, pS145 

    Testosterone deficiency, or hypogonadism, is common and may have deleterious effects on men, including decreased overall well-being, reduced sexual function and bone loss. Despite data demonstrating strong links between testosterone deficiency and significant comorbid conditions (including type...

  • Cardiovascular Disease In Men And Women--Does Declining Testosterone Play A Role?  // Life Extension;Jun2015, p19 

    The article discusses research being done on gender as a risk factor for cardiovascular disease, which references an article by Sanjai Sinha of Weill Cornell Medical College in New York published in the medical news Web site MedPage Today.

  • Management of Erectile Dysfunction in the Hypogonadal Man: A Case-Based Review. Ramasamy, Ranjith; Scovell, Jason M.; Wilken, Nathan A.; Kovac, Jason R.; Lipshultz, Larry I. // Reviews in Urology;2014, Vol. 16 Issue 3, p105 

    Erectile dysfunction (ED) has emerged as an important marker of cardiovascular and overall health, independent of other known conventional risk factors. ED often precedes coronary artery disease in half of affected subjects, and could indicate the presence of cardiovascular pathology. The...

  • Is androgen depletion for metastatic prostate cancer a risk factor for cardiovascular events? Stamatiou, K.; Dilernia, G. // Scientific Chronicles / Epistimonika Chronika;Oct2013, Vol. 18 Issue 4, p245 

    Cardiovascular disease is one of the most common causes of death worldwide and the most usual in the western populations. Although it affects both sexes, it is more frequent in males in whom it shortens the average life expectancy. This difference has been attributed to the negative effects of...

  • New trends in androgen deprivation therapy: Summary of key research presented at AUA 2014. Fleshner, Neil E. // Canadian Urological Association Journal;jui/aou2014 supplement 4, pS134 

    At the 2014 Annual Meeting of the American Urological Association (AUA), there were a number of educational sessions presenting new research regarding the use of androgen deprivation therapy (ADT). Two important themes related to ADT that emerged during the conference were the relationship...

  • Smoking, sex, risk factors and abdominal aortic aneurysm: is it all down to testosterone? Schooling, C. Mary // Journal of Epidemiology & Community Health;May2015, Vol. 69 Issue 5, p495 

    A letter to the editor is presented in response to the article "Smoking, sex, risk factors and abdominal aortic anerysms: a prospective study of 18782 persons aged above 65 years in the Southern Community Cohort Study" by E. Jahangir and colleagues in the 2015 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics